Navigation Links
Promising drug combination may help those with ocular melanoma that has spread
Date:9/4/2007

DURHAM, N.C. -- A combination of two drugs shows promise in treating a rare and therapy-resistant type of melanoma that originates in the eye and spreads to other organs, according to a new study led by Duke University Comprehensive Cancer Center researchers.

The drugs -- decitabine, which can turn on certain genes in cancer cells, and interferon gamma, an immune system protein -- may work together to cause cancer cell death.

Metastatic uveal melanoma, or melanoma that originates in the eye and spreads to other parts of the body, has been very difficult to treat, in fact there have been no effective therapies to date, said Jared Gollob, M.D., a medical oncologist at Duke and lead investigator on the study. This study could lead to a very promising new therapy for patients who previously had very little hope.

The researchers published their findings in the September 1, 2007 issue of the journal Clinical Cancer Research. The study was funded by the National Institutes of Health.

This pre-clinical study came on the heels of previous lab work examining proteins called interferons, which originate from immune system cells. These proteins were shown to boost immune function and directly affect melanoma cells, inhibiting their growth and accelerating their death, Gollob said.

We also knew that a drug called decitibine could turn on genes that had been turned off in cancer cells, so we speculated that if we combined decitabine and interferon gamma, we might see heightened cell death, and thats exactly what happened, Gollob said. Decitabine may turn on a certain gene, called S100A2, that is, in turn, able to increase the sensitivity of cancer cells to interferon gamma, he said.

Researchers used human cell lines, derived from patients who had been diagnosed with uveal melanoma, for this study. The next step will be a clinical study looking at the effectiveness of this drug combination in human subjects, Gollob said.

Uveal melanoma affects about 5,000 to 10,000 people each year in the United States. Unlike its counterpart on the skin, there are no known risk factors, Gollob said.

There are really no truly effective treatments for this devastating disease, he said. So this study really is a promising step toward finding a therapy that can really help these patients.

Uveal melanoma originates in the colored part of the eye, and symptoms include changes in vision, such as blurriness. If found early, it can be treated with radiation or with removal of the eye. When it spreads, uveal melanoma is typically unresponsive to standard treatment regimens, such as chemotherapy, Gollob said. Life expectancy once the disease has spread is about six to ten months, on average, he said.


'/>"/>

Contact: Lauren Shaftel Williams
lauren.shaftel@duke.edu
919-684-4966
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. PCR emerging as a promising technique for Diagnosing Urinary Tuberculosis
2. Experimental treatment for Ebola Virus Shows promising results in mice
3. A promising treatment for wart removal
4. Hepatitis shots is promising
5. Promising Treatment for Diabetes
6. Life after Bypass not so Promising for Women.
7. Promising cure for West Nile Virus
8. Deadly Diarrhoea Vaccine – Trail Results Promising
9. Novartis MS Drug Shows Promising Results
10. Sunitinib a Promising Agent for Treatment of Renal Cell Cancer
11. Research Ethics Requirements Compromising Quality of Health Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers ... to help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare ... Access and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... 72 percent of those report that family members or friends have also commented ... suffer from hearing loss wear hearing aids. One reason, suggested by 89 percent ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a nonprofit mental ... Established in 1977, our organization was at the forefront in working with veterans ... life were evident and served as the catalyst for the establishing the agency. ...
(Date:2/22/2017)... Dallas, Texas (PRWEB) , ... February 22, 2017 ... ... mobile enterprise solutions for supply chain management (SCM) and spend management, today announced ... reduce cost, save time, and simplify expense tracking. , “We are excited ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... Philpart, senior director at PolicyLink, will be the keynote speaker at its second ... and Men of Color Framework, which develops comprehensive strategies to create and expand ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Fla. , Feb. 22, 2017  Corin Group ... System, a device used to treat patients with both ... of shoulder arthritis. The condition, known as cuff tear ... and shoulder. The Humelock Reversed Shoulder ... upper extremities technology company based near Lyon, ...
(Date:2/22/2017)... , February 22, 2017 A ... Synthesis Modules Market: Global Opportunity Analysis and Industry Forecast, 2014-2022," ... $20 million in 2015 and projected to reach $32 million ... to 2022. North America accounted for ... unit volumes, whereas Asia-Pacific region is ...
(Date:2/22/2017)...  Known for selling everyday household products commonly ... prominent California urologist Dr. ... about the British conglomerate that makes those products – ... steal her late husband,s invention, business plans, and other ... Gilbert until his violent death in 2013, filed suit ...
Breaking Medicine Technology: